Iovance Biotherapeutics’ $150 Million Common Stock Public Offering

Pietro Martinoia North America Legal Chronicle
Tagged:

DLA Piper advised Iovance, and Latham & Watkins advised the underwriters.Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) announced the pricing of an underwritten public offering of 20,000,000 shares of…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:

Author: Pietro Martinoia

…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here